Lead Product(s): Stem cell therapy
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Innovate UK
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Funding May 13, 2021
This grant will fund a £3.2 million project to further develop Rinri’s novel stem cell therapy to reverse sensorineural hearing loss (SNHL) an area / a condition where there remains a significant global unmet need.